Companies › Shandong Boan Biotechnology
6 active drug programs in 6 registered trials: 5 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LY01015 PD-1 inhibitor | – | Phase 3 | Esophageal Squamous Cell Carcinoma | – |
| BA1202 | – | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| BA1301 | – | Phase 1 | Advanced Solid Tumours | Jun 2027 |
| BA1106 | – | Phase 1 | Solid Tumors | Dec 2027 |
| BA1302 | – | Phase 1 | Non-Small Cell Lung Cancer | Dec 2027 |
| BA1203 | – | Phase 1 | Solid Tumors | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06022861 | LY01015 | Phase 3 | Esophageal Squamous Cell Carcinoma | Oncology | May 2026 |
| NCT05909241 | BA1202 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT06927349 | BA1301 | Phase 1 | Advanced Solid Tumours | Oncology | Jun 2027 |
| NCT05650242 | BA1106 | Phase 1 | Solid Tumors | Oncology | Dec 2027 |
| NCT06596915 | BA1302 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT07876609 | BA1203 | Phase 1 | Solid Tumors | Oncology | Dec 2028 |
No annotated target.
–
TORL Biotherapeutics Nanjing Sanhome Pharmaceutical Taiho Pharmaceutical Minghui Pharmaceutical (Hangzhou) Day One Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.